Shareholder alert: weiss law investigates antares pharma, inc.

New york , april 13, 2022 /prnewswire/ -- weiss law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of antares pharma, inc. ("antares" or the "company") (nasdaq: atrs), in connection with the proposed acquisition of the company by halozyme therapeutics, inc. (nasdaq: halo) via a tender offer.  under the terms of the merger agreement, the company's shareholders will receive $5.60 in cash for each share of antares common stock owned.
ATRS Ratings Summary
ATRS Quant Ranking